Affiliation:
1. Department of Medicine, University of Utah College of Medicine, Salt Lake City, Utah.
2. Division of Hematology, University of Utah College of Medicine, Salt Lake City, Utah.
3. University of Utah College of Medicine, Salt Lake City, Utah.
Abstract
Abstract
In a 10-yr observation period, 75 patients with multiple myeloma have been studied, and 55 of these were treated daily with low dose melphalan by mouth. Of these, four developed sideroblastic anemia, manifested by anemia, thrombocytopenia, aniso-poikilocytosis, and hypochromic stippled cells in the blood, and ringed sideroblasts in the bone marrow. In two patients, this complication occurred after more than 7 yr of therapy and at a time when there was no evidence of myeloma. In a third patient, it occurred when the myeloma relapsed, and in the fourth, myeloma was active but stable. The anemia did not respond to either folate or pyridoxine. In all four patients, acute myelomonoblastic leukemia developed within 6 mo after sideroblastic anemia had been detected. These observations suggest that sideroblastic anemia in myeloma is a preleukemic manifestation.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Cited by
81 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Therapy-Related Acute Myelogenous Leukemia;Neoplastic Diseases of the Blood;2017-09-09
2. Therapy-Related Acute Myelogenous Leukemia;Neoplastic Diseases of the Blood;2012-07-27
3. Therapy-Related Myeloid Neoplasms;American Journal of Clinical Pathology;2009-09-01
4. The Preleukemic Syndrome;Acta Medica Scandinavica;2009-04-24
5. Melphalan-Related Leukemia in Multiple Myeloma;Acta Medica Scandinavica;2009-04-24